In research settings, scientists isolate and study this peptide to better understand its chemical stability, molecular structure, and interaction with biological systems under controlled conditions
Safety data from trials In a paper summarizing 6 randomized, double-blind, placebo-controlled human trials, AOD 9604 did not significantly affect IGF-1 levels, did not impair glucose tolerance, and no serious adverse events (SAEs) were attributed to AOD 9604
Only when BPC 157 was cumulatively added up to 10 or 100 g/ml, the increase of vasorelaxation became prominent
There are several reasons why you might consider this treatment
Adding too little water creates a very concentrated solution that may be more painful to inject, while too much water makes the injection volume unnecessarily large
Pregnancy and breastfeeding: avoid no safety data